(Q33582633)

28 July 2017

A reappraisal of economic evaluation of pharmaceuticals. Science or marketing? (English)

1 reference

28 July 2017

Drummond MF

1

1 reference

28 July 2017

1 July 1998

1 reference

28 July 2017

1 reference

28 July 2017

14

1 reference

28 July 2017

1

1 reference

28 July 2017

1-9

1 reference

https://scigraph.springernature.com/pub.10.2165/00019053-199814010-00001

28 July 2017

0 references

cites work

The journal's policy on cost-effectiveness analyses.

1 reference

12 December 2020

Ethics, economics, and the publication policies of major medical journals

1 reference

12 December 2020

Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology

1 reference

12 December 2020

A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).

1 reference

12 December 2020

Economic evaluation of pharmaceuticals: science or marketing?

1 reference

12 December 2020

Is there a need for an independent centre for pharmacoeconomics in the UK?

1 reference

12 December 2020

Issues in the design of studies for the economic evaluation of new atypical antipsychotics: the ESTO study

1 reference

12 December 2020

Manufacturing consensus, marketing truth: guidelines for economic evaluation

1 reference

12 December 2020

A proposal for Italian guidelines in pharmacoeconomics The Mario Negri Institute Centre for Health Economics

1 reference

12 December 2020

Economic evaluation techniques in healthcare. Reinventing the wheel?

1 reference

12 December 2020

Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals

1 reference

12 December 2020

Economic evaluation of pharmaceuticals: a critical appraisal of seven studies on cholesterol-lowering agents

1 reference

12 December 2020

Economic evaluation under managed competition: evidence from the U.K.

1 reference

12 December 2020

Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies.

1 reference

12 December 2020

Evaluating the BMJ guidelines for economic submissions: prospective audit of economic submissions to BMJ and The Lancet

1 reference

12 December 2020

Relationships between sponsors and investigators in pharmacoeconomic and clinical research

1 reference

12 December 2020

Economic evaluation and clinical uncertainty: response to Freemantle and Maynard

1 reference

12 December 2020

Economic analysis of health technologies and programmes. A Spanish proposal for methodological standardisation

1 reference

12 December 2020

Something rotten in the state of clinical and economic evaluations?

1 reference

12 December 2020

Industry responsibility in interactive computer modeling

1 reference

12 December 2020

Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party

1 reference

12 December 2020

Health economics in primary care in the UK: containment of drug costs

1 reference

12 December 2020

Applying the Australian guidelines for the reimbursement of pharmaceuticals

1 reference

12 December 2020

Publication bias in health economic studies

1 reference

12 December 2020

10.2165/00019053-199814010-00001

Identifiers

DOI

1 reference

PubMed ID

10182189

Dimensions Publication ID

28 July 2017

0 references

1 reference

PubMed ID

10182189